Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.
Hemogenyx Pharmaceuticals Plc has announced its final results for the year ended December 31, 2024, highlighting significant progress in its clinical programs and financial stability. The company successfully commenced Phase I clinical trials for its HG-CT-1 CAR-T cell therapy, raised over £5 million in funding, and expanded its clinical reach through strategic partnerships, positioning itself strongly in the biopharmaceutical industry despite challenging market conditions.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a biopharmaceutical company focused on developing innovative therapies and treatments for blood diseases. The company is actively engaged in clinical-stage development, particularly in CAR-T cell therapy for acute myeloid leukemia, and is also advancing its Chimeric Bait Receptor antiviral/biodefense platform.
YTD Price Performance: -54.75%
Average Trading Volume: 37,092
Technical Sentiment Signal: Buy
Current Market Cap: £7.5M
See more data about HEMO stock on TipRanks’ Stock Analysis page.